ASCENT-04 Study: TROP2 ADC SG Combined with Keytruda Establishes New First-Line Standard for PDL1+ Triple-Negative Breast Cancer
The ASCENT-04 study is a global, multicenter, randomized, open-label phase III clinical trial designed to evaluate the efficacy and safety of the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab govitecan (SG) combined with the PD-1 inhibitor pembrolizumab (Keytruda, K drug) compared to chemotherapy combined with K drug in first-line treatment of PD-L1 positive (CPS≥10) metastatic triple-negative breast … Read more